Eli Lilly has succeeded in its attempt to get the first non-covalent version of Bruton's tyrosine kinase, or BTK, inhibitors to market, pushing it past rival Merck. The FDA gave an accelerated nod to Lilly's daily oral med, to be sold as Jaypirca, for patient…